American Cancer Society. Coriolus VersicolorArchived 2010年6月25日, at the Wayback Machine. Last Medical Review: 11/01/2008. Last Revised: 11/01/2008. Accessed May 10, 2014
doi.org
Strebhardt K, Ullrich A (Jun 2008). “Paul Ehrlich's magic bullet concept: 100 years of progress”. Nature Reviews. Cancer8 (6): 473–80. doi:10.1038/nrc2394. PMID18469827.
Waldmann TA (Mar 2003). “Immunotherapy: past, present and future”. Nature Medicine9 (3): 269–77. doi:10.1038/nm0303-269. PMID12612576.
Gardner TA, Elzey BD, Hahn NM (Apr 2012). “Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer”. Human Vaccines & Immunotherapeutics8 (4): 534–9. doi:10.4161/hv.19795. PMID22832254.
Oudard S (May 2013). “Progress in emerging therapies for advanced prostate cancer”. Cancer Treatment Reviews39 (3): 275–89. doi:10.1016/j.ctrv.2012.09.005. PMID23107383.
Sims RB (Jun 2012). “Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer”. Vaccine30 (29): 4394–7. doi:10.1016/j.vaccine.2011.11.058. PMID22122856.
Scott AM, Wolchok JD, Old LJ (Apr 2012). “Antibody therapy of cancer”. Nature Reviews. Cancer12 (4): 278–87. doi:10.1038/nrc3236. PMID22437872.
Harding FA, Stickler MM, Razo J, DuBridge RB (May–Jun 2010). “The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions”. mAbs2 (3): 256–65. doi:10.4161/mabs.2.3.11641. PMID20400861.
Weiner LM, Surana R, Wang S (May 2010). “Monoclonal antibodies: versatile platforms for cancer immunotherapy”. Nature Reviews. Immunology10 (5): 317–27. doi:10.1038/nri2744. PMID20414205.
Seidel UJ, Schlegel P, Lang P (2013). “Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies”. Frontiers in Immunology4: 76. doi:10.3389/fimmu.2013.00076. PMID23543707.
Gelderman KA, Tomlinson S, Ross GD, Gorter A (Mar 2004). “Complement function in mAb-mediated cancer immunotherapy”. Trends in Immunology25 (3): 158–64. doi:10.1016/j.it.2004.01.008. PMID15036044.
Pardoll DM (Apr 2012). “The blockade of immune checkpoints in cancer immunotherapy”. Nature Reviews. Cancer12 (4): 252–64. doi:10.1038/nrc3239. PMID22437870.
Pardoll DM (Apr 2012). “The blockade of immune checkpoints in cancer immunotherapy”. Nature Reviews. Cancer12 (4): 252–64. doi:10.1038/nrc3239. PMID22437870.
Dranoff G (Jan 2004). “Cytokines in cancer pathogenesis and cancer therapy”. Nature Reviews. Cancer4 (1): 11–22. doi:10.1038/nrc1252. PMID14708024.
Dunn GP, Koebel CM, Schreiber RD (Nov 2006). “Interferons, immunity and cancer immunoediting”. Nature Reviews. Immunology6 (11): 836–48. doi:10.1038/nri1961. PMID17063185.
Lasfar A, Abushahba W, Balan M, Cohen-Solal KA (2011). “Interferon lambda: a new sword in cancer immunotherapy”. Clinical & Developmental Immunology2011: 349575. doi:10.1155/2011/349575. PMID22190970.
Ahmed M, Cheung NK (Jan 2014). “Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy”. FEBS Letters588 (2): 288–97. doi:10.1016/j.febslet.2013.11.030. PMID24295643.
Aleem E (Jun 2013). “β-Glucans and their applications in cancer therapy: focus on human studies”. Anti-Cancer Agents in Medicinal Chemistry13 (5): 709–19. doi:10.2174/1871520611313050007. PMID23140353.
Gardner TA, Elzey BD, Hahn NM (Apr 2012). “Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer”. Human Vaccines & Immunotherapeutics8 (4): 534–9. doi:10.4161/hv.19795. PMID22832254.
Oudard S (May 2013). “Progress in emerging therapies for advanced prostate cancer”. Cancer Treatment Reviews39 (3): 275–89. doi:10.1016/j.ctrv.2012.09.005. PMID23107383.
Sims RB (Jun 2012). “Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer”. Vaccine30 (29): 4394–7. doi:10.1016/j.vaccine.2011.11.058. PMID22122856.
Shore ND, Mantz CA, Dosoretz DE, Fernandez E, Myslicki FA, McCoy C, Finkelstein SE, Fishman MN (Jan 2013). “Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer”. Cancer Control20 (1): 7–16. PMID23302902.
Scott AM, Wolchok JD, Old LJ (Apr 2012). “Antibody therapy of cancer”. Nature Reviews. Cancer12 (4): 278–87. doi:10.1038/nrc3236. PMID22437872.
Harding FA, Stickler MM, Razo J, DuBridge RB (May–Jun 2010). “The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions”. mAbs2 (3): 256–65. doi:10.4161/mabs.2.3.11641. PMID20400861.
Weiner LM, Surana R, Wang S (May 2010). “Monoclonal antibodies: versatile platforms for cancer immunotherapy”. Nature Reviews. Immunology10 (5): 317–27. doi:10.1038/nri2744. PMID20414205.
Seidel UJ, Schlegel P, Lang P (2013). “Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies”. Frontiers in Immunology4: 76. doi:10.3389/fimmu.2013.00076. PMID23543707.
Gelderman KA, Tomlinson S, Ross GD, Gorter A (Mar 2004). “Complement function in mAb-mediated cancer immunotherapy”. Trends in Immunology25 (3): 158–64. doi:10.1016/j.it.2004.01.008. PMID15036044.
Pardoll DM (Apr 2012). “The blockade of immune checkpoints in cancer immunotherapy”. Nature Reviews. Cancer12 (4): 252–64. doi:10.1038/nrc3239. PMID22437870.
Pardoll DM (Apr 2012). “The blockade of immune checkpoints in cancer immunotherapy”. Nature Reviews. Cancer12 (4): 252–64. doi:10.1038/nrc3239. PMID22437870.
Dranoff G (Jan 2004). “Cytokines in cancer pathogenesis and cancer therapy”. Nature Reviews. Cancer4 (1): 11–22. doi:10.1038/nrc1252. PMID14708024.
Dunn GP, Koebel CM, Schreiber RD (Nov 2006). “Interferons, immunity and cancer immunoediting”. Nature Reviews. Immunology6 (11): 836–48. doi:10.1038/nri1961. PMID17063185.
Lasfar A, Abushahba W, Balan M, Cohen-Solal KA (2011). “Interferon lambda: a new sword in cancer immunotherapy”. Clinical & Developmental Immunology2011: 349575. doi:10.1155/2011/349575. PMID22190970.
Ahmed M, Cheung NK (Jan 2014). “Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy”. FEBS Letters588 (2): 288–97. doi:10.1016/j.febslet.2013.11.030. PMID24295643.
Aleem E (Jun 2013). “β-Glucans and their applications in cancer therapy: focus on human studies”. Anti-Cancer Agents in Medicinal Chemistry13 (5): 709–19. doi:10.2174/1871520611313050007. PMID23140353.
American Cancer Society. Coriolus VersicolorArchived 2010年6月25日, at the Wayback Machine. Last Medical Review: 11/01/2008. Last Revised: 11/01/2008. Accessed May 10, 2014